Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Anju Ghangurde

Anju Ghangurde is Scrip's Deputy Asia Editor and has about two decades of experience in journalism including stints at India's mainstream financial dailies -The Economic Times, The Hindu Business Line and The Financial Express.  She covers a broad range of issues including competition and collaboration between generics and innovator firms, drug pricing and the evolving regulatory and legal framework in the region. She is also a recipient of the British Chevening Scholarship for Young Indian Journalists (2000-01) awarded by the Foreign & Commonwealth Office.
Set Alert for Articles By Anju Ghangurde

Latest From Anju Ghangurde

Deal Watch: Ionis Turns To Affiliate Akcea In Amyloidosis

Biohaven restructures its migraine partnership with Bristol to reduce its downstream royalty commitments. Meanwhile, the pharma partners with GRYT Health's cancer app for patient/caregiver insights into cancer therapy.

Deals M & A

Curatio Nets $20m Investment As Dermatology Stays On PE Menu

Private equity group ChrysCapital is investing $20m in the Indian firm Curatio Healthcare, underscoring the continuing interest in the niche dermatology space that generally sees healthy margins.

Commercial Strategy

Sanofi’s Larsen On Advances In Diabetes R&D And Payer Expectations

Dr Philip Larsen, Vice President, Research and Translational Medicine, R&D Diabetes Division, Sanofi tells Scrip in an interview which way potential gene therapy for diabetes may be headed and how the Sanofi-Evotec alliance is shaping. He also indicates that oral insulin, considered the holy grail of diabetes treatment, is a ‘really long journey’ with difficult prospects currently.

Research & Development Clinical Trials

Signs Of Improving FDA Inspection Outcomes At Indian Sites But Long Road Ahead

Moving up the manufacturing compliance curve is still a work in progress for several Indian firms, but there appear to be some early signs that US FDA inspection outcomes, in general, may have improved.
Manufacturing Compliance

Novartis’s Chief Medical Officer On All Things MS And The Science Of Operations

Shreeram Aradhye, Novartis’s Global Head, Medical Affairs, and Chief Medical Officer (Pharmaceuticals), outlines the company’s all-encompassing-approach for multiple sclerosis therapies. In a wide-ranging interview with Scrip, Aradhye also touches on the promise of gene therapy and how emerging technologies are helping shape medical innovation.

Commercial Strategy

How Sanofi Is Stepping Up Blue Sky Research With Academia

French multinational Sanofi is keen to take global its iAwards program that is designed to back early stage innovative and translational research proposals from participating academic institutions. Plans are afoot to expand the initiative in Asia and build on its success in the US, Sridaran Natesan, head of strategic initiatives and scientific relations (North America), tells Scrip in an interview.
Strategy Research and Development Strategies
See All